Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 3/20 | 0.62 |
| ▸ | TOP2B | Q02880 | 3/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9752758 | 1.00 | TOP2A (0.62) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| SCHEMBL9752445 | 0.88 | TOP2A (0.50) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Dexrazoxane SCHEMBL1586271 | 0.77 | TOP2A (1.00) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Dexrazoxane SCHEMBL18400 | 0.77 | TOP2A (1.00) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Razoxane SCHEMBL9089 | 0.77 | TOP2A (1.00) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Razoxane SCHEMBL3339694 | 0.77 | TOP2A (1.00) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Razoxane SCHEMBL27748349 | 0.76 | TOP2A (0.96) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Dexrazoxane SCHEMBL18188 | 0.76 | TOP2A (0.96) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Razoxane SCHEMBL27174203 | 0.76 | TOP2A (0.96) | TOP2ATOP2BPTGS1LMNAALDH1A1 | |
| Dexrazoxane SCHEMBL18189 | 0.74 | TOP2A (0.93) | TOP2ATOP2BPTGS1LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2575810-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUND AND A TOPOISOMERASE II INHIBITOR | Synta Pharmaceuticals Corp. (US) | 2013-04-10 | — | — | EP | claimed |
| WO-2011149824-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUND AND A TOPOISOMERASE II INHIBITOR | SYNTA PHARMACEUTICALS CORP. (US) | 2011-12-01 | — | — | WO | claimed |
| JP-2011524851-A | — | — | 2011-09-08 | — | — | JP | claimed |
| EP-2242360-A2 | DOXORUBICIN ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME | Tosk, Inc. (US) | 2010-10-27 | — | — | EP | claimed |
| WO-2009102808-A2 | DOXORUBICIN ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME | TOSK, INCORPORATED (US) | 2009-08-20 | — | — | WO | claimed |
| WO-1991000729-A2 | BIS-DIOXOPIPERAZINES, AND THEIR USE AS PROTECTING AGENTS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1991-01-24 | — | — | WO | claimed |
| EP-0409499-A2 | Pharmaceutical compositions | BTG INTERNATIONAL LIMITED (GB) | 1991-01-23 | — | — | EP | claimed |
| WO-2021144746-A1 | USE OF ICRF-193 DERIVATIVES AND PHARMACEUTICAL PREPARATIONS CONTAINING THEREOF FOR THE PREVENTION OF CHRONIC CUMULATIVE CARDIOTOXICITY CAUSED BY THERAPY WITH ANTHRACYCLINE ANTICANCER DRUGS | UNIVERZITA KARLOVA V PRAZE (CZ) | 2021-07-22 | — | — | WO | disclosed |
| WO-2018160758-A1 | USE OF DIANHYDROGALACTITOL OR ANALOGS AND DERIVATIVES IN COMBINATION WITH A P53 MODULATOR OR A PARP INHIBITOR | BACHA JEFFREY A (CA) | 2018-09-07 | — | — | WO | disclosed |
| US-9468613-B2 | Doxorubicin adjuvants to reduce toxicity and methods for using the same | TOSK, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-20150258046-A1 | Doxorubicin Adjuvants to Reduce Toxicity and Methods for Using the Same | TOSK, INC. | 2015-09-17 | — | — | US | disclosed |
| US-9061038-B2 | Doxorubicin adjuvants to reduce toxicity and methods for using the same | TOSK, INCORPORATED (US) | 2015-06-23 | — | — | US | disclosed |
| EP-2242360-B1 | DOXORUBICIN ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME | TOSK INC (US) | 2015-04-08 | — | — | EP | disclosed |
| US-20100144704-A1 | Method of reducing amyloid-beta peptide levels using a bisdioxopiperazine | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2010-06-10 | — | — | US | disclosed |
| US-20090325893-A1 | DOXORUBICIN ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME | TOSK, INCORPORATED | 2009-12-31 | — | — | US | disclosed |
| WO-2009102808-A2 | DOXORUBICIN ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME | TOSK, INCORPORATED (US) | 2009-08-20 | — | — | WO | disclosed |
| EP-2035003-A1 | A METHOD OF REDUCING AMYLOID-BETA PEPTIDE LEVELS USING A BISDIOXOPIPERAZINE | The Govt Of The USA, As Represented By The Secretary, Department Of Health And Human Services (US) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007146178-A1 | A METHOD OF REDUCING AMYLOID-BETA PEPTIDE LEVELS USING A BISDIOXOPIPERAZINE | THE GOVT OF THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-1991000729-A2 | BIS-DIOXOPIPERAZINES, AND THEIR USE AS PROTECTING AGENTS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1991-01-24 | — | — | WO | disclosed |
| EP-0409499-A2 | Pharmaceutical compositions | BTG INTERNATIONAL LIMITED (GB) | 1991-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144704-A1 | Method of reducing amyloid-beta peptide levels using a bisdioxopiperazine | IAPP, APP, BACE1 | TOP2A 2986/4885TOP2B 2227/4885PTGS1 3563/4885 |
| US-20150258046-A1 | Doxorubicin Adjuvants to Reduce Toxicity and Methods for Using the Same | TOP2A, TLR5, MYD88 | TOP2A 1/4885TOP2B 5/4885PTGS1 384/4885 |
| US-20090325893-A1 | DOXORUBICIN ADJUVANTS TO REDUCE TOXICITY AND METHODS FOR USING THE SAME | TOP2A, TLR5, MYD88 | TOP2A 1/4885TOP2B 5/4885PTGS1 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.